Join Growin Stock Community!

Regencell bioscience holdings limitedRGC.US Overview

US StockHealthcare
(No presentation for RGC)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

RGC AI Insights

RGC Overall Performance

RGC AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

RGC Recent Performance

-1.46%

Regencell bioscience holdings limited

0.05%

Avg of Sector

-0.31%

S&P500

RGC PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

RGC Key Information

RGC Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

RGC Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Price of RGC

RGC FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

RGC Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.01
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
2668.67
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
25.99%
3-Year Profit Growth
25.99%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.01
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
2668.67
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
25.99%
3-Year Profit Growth
25.99%

  • When is RGC's latest earnings report released?

    The most recent financial report for Regencell bioscience holdings limited (RGC) covers the period of 2025Q4 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating RGC's short-term business performance and financial health. For the latest updates on RGC's earnings releases, visit this page regularly.

  • How much debt does RGC have?

    As of the end of the reporting period, Regencell bioscience holdings limited (RGC) had total debt of 544.42K, with a debt ratio of 0.09. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does RGC have?

    At the end of the period, Regencell bioscience holdings limited (RGC) held Total Cash and Cash Equivalents of 2.42M, accounting for 0.42 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.